Vascular occlusion

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Retrieved on: 
Monday, March 18, 2024
Research, Adverum Biotechnologies, Vasculitis, Three Months, Macula, Chorioretinitis, Inflammation, Patient, Episcleritis, American Academy, Anti-VEGF, LUNA, Intraocular pressure, Investment, Clinical trial, Injection, Safety, Drug development, Paratriathlon, AMD, AAO, OPTIC, Retinitis, CST, Vascular occlusion, Annual general meeting, VEGF, Pharmaceutical industry

REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023. The company also provided recent pipeline highlights and corporate updates.

Key Points: 
  • The company also provided recent pipeline highlights and corporate updates.
  • 85% and 68% of patients at the 2E11 and 6E10 doses, respectively, received no supplemental injections through 26 weeks.
  • Stock-based compensation expense included in research and development expenses was $1.0 million for the fourth quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the fourth quarter of 2023.

Innovating "Treadmill Exercise Test AI-Assisted Interpretation System," CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

Retrieved on: 
Tuesday, April 2, 2024
Depression, Thrombosis, Myocardial infarction, Sudden death, Cardiovascular disease, Exercise, Survival, Coronary artery disease, ECG, Hyperlipidemia, Patient, Palpitations, Angina, Cancer, AI, Death, Moyamoya disease, Chronic pain, Plaque, Diet, Receiver, Smoking, Cardiac catheterization, Stenosis, Oxygen, Heart, Atherosclerosis, Rupture, Ministry, Duke, Vascular occlusion, CAD

To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.

Key Points: 
  • To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.
  • The program also utilizes ten measured features and two derived features including maximal work output and peak heart rate to determine the severity of coronary artery stenosis.
  • Generally, coronary heart disease in patients of middle or senior age is presented as angina or myocardial infarction and is one of the primary causes of sudden death."
  • Dr. Wu stated, "Coronary artery stenosis is a multi-factorial condition related to smoking, advanced age, diabetes hypertension and hyperlipidemia.

Enhancing Your Lips: Lip Flips vs. Lip Fillers

Retrieved on: 
Tuesday, February 27, 2024
Internet, Injection, Allergy, Bruise, Multimedia, Pain, Infection, Day, Injectable filler, Vascular occlusion, Swelling, Risk, Mouth, Safety, Hyaluronic acid, Lip, Tissue, Anesthetic, Cosmetics

When deciding between lip flips and lip filler, it's essential to consider your aesthetic goals, budget, and comfort level with each procedure.

Key Points: 
  • When deciding between lip flips and lip filler, it's essential to consider your aesthetic goals, budget, and comfort level with each procedure.
  • Let's dispel some of the most common misconceptions about lip flips and lip fillers.
  • Typically, the effects of lip fillers endure for around six months to one year, while lip flips generally last between 6 to 8 weeks.
  • Some people think that lip flips and lip fillers can cause long-term damage or change the structure of the lips.

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Retrieved on: 
Thursday, February 8, 2024
Chorioretinitis, Injection, Principal, Inflammation, Life, Adverum Biotechnologies, VEGF, AMD, Partner (business rank), Vasculitis, Patient, Safety, Paratriathlon, Prednisone, University of Nevada, Reno, Intraocular pressure, Data, Webcast, University, Retinitis, M.A, Clinical research, CST, Vascular occlusion, Pharmaceutical industry

These data are being presented by Dr. Arshad Khanani today at the 47th Annual Meeting of the Macula Society.

Key Points: 
  • These data are being presented by Dr. Arshad Khanani today at the 47th Annual Meeting of the Macula Society.
  • “Wet AMD is a leading cause of blindness in people over the age of 65, requiring life-long anti-VEGF injections.
  • Our goal with Ixo-vec is to provide patients virtually injection-free management of their wet AMD lasting years and potentially for life,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
  • The LUNA trial builds on our experience with the OPTIC study, where landmark 2-year data was recently published in The Lancet’s eclinicalmedicine.

Alio Officially Enters GCC Market Through Partnership with Al Redwan

Retrieved on: 
Tuesday, December 5, 2023
Calibration, Vascular occlusion, Chronic kidney disease, ESKD, Potassium, Kidney disease, Patient, Dialysis, Kidney, FDA, Hematocrit, Auscultation, Blood, Partnership, Death, Hospital, Quality of life, Health, Alió, Kingdom

BROOMFIELD, Colo., Dec. 5, 2023 /PRNewswire/ -- Today, Alio, Inc. announces its strategic partnership with Al Redwan Medical Services Company, a leader in dialysis and medical lab trading and medical services in the Gulf region. Alio, already commercially available in the United States, has expanded its global presence to the Kingdom of Saudi Arabia to reach a greater number of kidney patients in need.

Key Points: 
  • The Alio Platform dramatically improves the technology solutions available to clinicians by delivering actionable, clinical-grade metrics and notifications at key intervention points.
  • Alio's partnership with Al Redwan allows Alio to manage the more than 3,000 End-Stage Kidney Disease (ESKD) patients for whom Al Redwan directly provides dialysis.
  • Beyond the patients already under Al Redwan's care, the partnership will also enable and facilitate the distribution of Alio products to other hospitals, providers, and partners in the region, including Diaverum.
  • Unfortunately, the technology available to date has only catered to one or two of their conditions," said Mr. Yousef Al Redwan, CEO of Al Redwan Medical Services.

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

Retrieved on: 
Friday, October 27, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, ROG, Food, Ranibizumab, RO, AMD, DME, Injection, Warning, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inflammation, Retinal vasculitis, RVO, Diabetic retinopathy, Colic flexures, Paratriathlon, Vascular occlusion, Roche, Eye, Macular edema, Neovascularization, Pharmaceutical industry, Vaccine, Faricimab, Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo® (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo® (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).
  • RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).
  • Together, the three retinal conditions affect around 3 million people in the U.S. and are among the leading causes of vision loss.
  • This was further supported by data showing Vabysmo achieved rapid and robust drying of retinal fluid.

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting

Retrieved on: 
Monday, July 31, 2023
Durability, Diabetes, Anti-VEGF, AMD, Pharming, Cohort, Aes, Eye, Clinical trial, TKI, Targeted therapy, Diabetic retinopathy, Retina, Inflammation, Extension, Șaeș, Melanoma, Patient, Physician, CST, Associate, Month, Biological effects of high-energy visible light, Vascular occlusion, Axitinib, Phase, Visual acuity, Society, ASRS, Safety, SCS, Pharmaceutical industry, MD

ALPHARETTA, Ga., July 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that safety and tolerability data from its recent OASIS clinical trial of CLS-AX (axitinib injectable suspension) were presented at the American Society of Retina Specialists (ASRS) 41st Annual Scientific Meeting. CLS-AX is a proprietary suspension formulation of the tyrosine kinase inhibitor (TKI) axitinib that provides high potency pan-VEGF inhibition delivered via Clearside’s proprietary SCS Microinjector®.

Key Points: 
  • CLS-AX is a proprietary suspension formulation of the tyrosine kinase inhibitor (TKI) axitinib that provides high potency pan-VEGF inhibition delivered via Clearside’s proprietary SCS Microinjector®.
  • The presentation, entitled, “Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy” was delivered by Rahul N. Khurana, MD, FACRS, Northern California Retina Vitreous Associates.
  • “The safety profile for new potential treatments in development for wet AMD and other retinal diseases is of paramount importance to physicians and patients.
  • CLS-AX has demonstrated an excellent safety profile to date with no adverse events, and in particular, no inflammation,” said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer.

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

Retrieved on: 
Thursday, February 2, 2023
OASIS, Standard of care, Vascular occlusion, CLS, Bausch & Lomb, Vasculitis, Durability, Conference call, Eye, Endophthalmitis, Management, Șaeș, Conference, Toxic epidermal necrolysis, Extension, AMD, University, Patient, University of Arizona College of Pharmacy, Cohort, Retina, Injection, Pressure, Biological effects of high-energy visible light, Axitinib, Clearside, Pharming, Inflammation, Pharmaceutical industry, Ophthalmology, Webcast

ALPHARETTA, Ga., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today positive results from the Extension Study of its OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector® in neovascular age-related macular degeneration (wet AMD) participants. These results include the final six-month data from all participants in the Extension Study and augment the previously reported 3-month results and interim extension data.

Key Points: 
  • These results include the final six-month data from all participants in the Extension Study and augment the previously reported 3-month results and interim extension data.
  • Thomas A. Ciulla, M.D., M.B.A., Chief Medical Officer and Chief Development Officer, said, “The positive data from our OASIS Extension Study reinforces our belief that CLS-AX has the potential to reduce treatment burden in patients with wet AMD while maintaining stable visual acuity.
  • In all participants in the trial, CLS-AX was well tolerated and demonstrated an excellent safety profile across all timepoints and doses.
  • The OASIS Phase 1/2a trial is complete for both the 3-month dose-escalation portion and the 3-month Extension Study.

Galderma and National Breast Cancer Foundation Announce Continued Partnership to Launch Campaign Elevating Skin Stories of Breast Cancer Survivors

Retrieved on: 
Monday, October 3, 2022
Lip, History, Toxin (comics), Anaphylaxis, Lists of diseases, Safety, Pimple, Warfarin, Skin discoloration, Allergy, Swelling, Vitamin, Coagulopathy, Cheek, Victory Unintentional, Myasthenia gravis, Skin, Bleeding, Face, Rash, Upper respiratory tract infection, Recurrence, Headache, Skin infection, Lidocaine, Human, Patient, Severe cognitive impairment, Infection, Blood, Nausea, Bruise, ALS, Inflammation, Muscle, Amyotrophic lateral sclerosis, Red, Medication, Restylane, Aspirin, Muscle weakness, Nose, Tenderness, Wound, Multimedia, Pain, FDA, Herbal, Cyst, Vascular occlusion, Risk, Scar, Bacteria, Hypertrophic scar, Stroke, Sculptra, Catherine Disher, Infarction, Death, Hyaluronic acid, Eyebrow, Laser, Galderma, Use, Cosmetics, Canning, Birth control, Dietary supplement, Pharmaceutical industry, Medicine, Tissue paper, Botulinum toxin

These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities.

Key Points: 
  • These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities.
  • Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal and other natural products.
  • Use at the site of skin sores, cysts, pimples, rashes, hives or infection should be postponed until healing is complete.
  • Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area.

Galderma to Present New Findings From Innovative Product Portfolio at the 2022 VCS Annual Symposium

Retrieved on: 
Wednesday, June 8, 2022
Science, Other Science, Biotechnology, Research, Surgery, Health, FDA, Clinical Trials, Blood, Wound, Inflammation, Pain, PLLA, Allergy, Toxin (comics), Vascular occlusion, Skin infection, Herbal, Muscle, History, Galderma, Hypertrophic scar, Tenderness, Human, Infection, Headache, Vitamin, Partnership, Bleeding, Myasthenia gravis, Red, Rash, Bajaj Consumer Care, Dermatology, Pimple, Sculptra, Catherine Disher, Infarction, Nausea, Bruise, Lip, Patient, ALS, Muscle weakness, Skin, Cyst, Skin discoloration, Use, Research, Nose, Medication, Amyotrophic lateral sclerosis, Upper respiratory tract infection, FDA, Risk, Face, Safety, Eyebrow, Death, Pharmaceutical industry, Cosmetics, Canning, Birth control, Dietary supplement, Medicine, Aesthetics, EU, Botulinum toxin, Ipsen

Galderma is the worlds largest independent dermatology company, present in approximately 100 countries.

Key Points: 
  • Galderma is the worlds largest independent dermatology company, present in approximately 100 countries.
  • We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine.
  • Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes.
  • Because we understand that the skin were in shapes our life stories, we are advancing dermatology for every skin story.